Rapport Therapeutics, Inc.RAPP

Rapport Therapeutics Inc. is a clinical-stage biotechnology company chasing precision neuromedicines, yet its latest SEC filing shows no approved products and no revenue from drug sales. The company’s 10-Q for the quarter ended 31 March 2026 reports $20 million in revenue-none from product sales-while racking up a $19.9 million net loss and negative $0.42 diluted EPS. The cash position stands at $78.1 million, but operating activities burned $13.1 million, and the company still owes up to $5.8 million to NeuroPace under a master services agreement signed in 2023.

The company’s public site and pipeline page promise “revolutionary” and “relentless” precision, but the SEC filing is the only place that tells the unvarnished truth: there are no commercial products, no paying customers, and no revenue from drugs. Precision Neuroscience’s discovery platform is real, but it has yet to translate into a single dollar of product revenue. The site’s hero images and receptor graphics are more polished than the income statement, a gap that grows harder to ignore with each filing.

Through 31 March 2026, the company had no products approved for commercial use and had not generated any revenue from product sales, according to the 10-Q. Research and development expense for the quarter was $32.7 million, while operating loss reached $24.2 million. The company’s cash and short-term investments total $476.8 million, but net cash used in operating activities was $13.1 million, and capital expenditure was a pocket-lint $86,000. The NeuroPace agreement commits the company to up to $5.8 million in payments over roughly four years for services tied to patient enrollment milestones that have not yet been disclosed as achieved.

For investors, the tension sits between the company’s polished platform narrative and the raw filings. The platform promises precision medicines for drug-resistant epilepsies and mood disorders, but the only concrete evidence is a receptor image on the website and a pipeline slide that stops at early-stage programmes. The company’s About page slogan-“Revolutionary. Relentless. Precise.”-reads less like a mission statement now and more like aspirational marketing when set against the 10-Q’s hard numbers.

The company’s pipeline image and receptor illustration are useful as visual aids, but they prove nothing about revenue, approvals, or clinical success. The official SEC filing remains the only authoritative source for operating results, cash, liabilities, and contractual commitments. The images on the company’s website complement the filings but do not replace them.

What changed this week is the continued absence of product revenue and the persistence of cash burn. The company’s diluted share count stands at 47.2 million, up from prior filings, reflecting ongoing equity issuance and the dilutive effect of warrants and options. The only concrete clinical signal is the company’s long-standing relationship with NeuroPace, a vendor relationship that obliges future payments rather than delivering immediate sales. The company’s website and pipeline graphics remain aspirational while the filing tells the measurable story.

The key question for the next filing is whether any programme has progressed to a stage that could plausibly translate into near-term revenue or a partnering event. Until then, the filings, not the website, are the only place to measure the gap between promise and performance.